PMC8172793_01
Brain MRI in November 2018 revealed multiple ischemic lesions, white matter degeneration and brain atrophy, including hippocampal atrophy.
fneur-12-656024-g0001.jpg
PMC8172793_01_fneur-12-656024-g0001.jpg
F1
One year ago, a brain magnetic resonance image (MRI) scan revealed multiple ischemic lesions, white matter degeneration and encephalatrophy, including hippocampal atrophy (Figure 1).
Human embryonic kidney 293 cells staining transfected with NR1 and NR1-NR2B subunits by using indirect immunofluorescence. As shown in this figure, the results were positive (200x).
fneur-12-656024-g0002.jpg
PMC8172793_01_fneur-12-656024-g0002.jpg
F2
Transfection of human embryonic kidney (HEK) 293 cells with NR1 subunit or NR1-NR2B subunits of NMDAR was performed to test for the presence of NMDAR antibody (Figure 2) and it was confirmed by using a commercial kit (Euroimmune, Germany) with both cell-based assay (CBA) and rat brain immunostaining.
Brain MRI in September 2019 before treatment showed new scattered foci of T2- FLAIR hyperintensity within the periventricular, deep and subcortical white matter of the frontoparietal lobe and progressive brain atrophy, especially in the hippocampus.
fneur-12-656024-g0003.jpg
PMC8172793_01_fneur-12-656024-g0003.jpg
F3
Brain MRI showed new scattered foci of T2-weighted-fluid-attenuated inversion recovery (FLAIR) hyperintensity within the periventricular, deep and subcortical white matter of the frontoparietal lobe without post-contrast enhancement (Figure 3).
Repeated brain MRI after 2 months of treatment in November 2019 showed the scattered foci of T2-FLAIR hyperintensity disappeared partially.
fneur-12-656024-g0004.jpg
PMC8172793_01_fneur-12-656024-g0004.jpg
F4
Repeated brain MRI after 2 months of treatment showed scattered foci of T2-FLAIR hyperintensity disappeared partially (Figure 4).